Nocion Therapeutics
2 known investors
Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves. The company is advancing taplucainium inhalation powder, a first-in-class therapy in Phase 2b clinical development for refractory and unexplained chronic cough, with potential applications in pain, itch, and other conditions driven by neurogenic inflammation.
BiotechHealthtechMedical Devices
Founders & leadership
R
Rick
J
Jim
Investors · 2
In the news
- About — Nocion Therapeutics - Nocion Therapeuticsnociontx.com · 2026
- Exclusive: Nocion raises $62M for different approach to chronic cough than Merck, GSKendpoints.news · 2024
- Nocion Therapeutics Announces $62 Million Series B Financing to Advance Lead Program in Cough into Later Stage Developmen — Nocion Therapeutics - Nocion Therapeuticsnociontx.com · 2024
- Nocion Therapeutics Raises $27M in Series A Funding - FinSMEsfinsmes.com · 2019
- Nocion Therapeutics $27 Million Series a for Non-Opioid Pain Drug - Business Insiderbusinessinsider.com · 2019